Abstract
Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5% solution administered twice daily versus timolol 0.1% in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5% solution or timolol 0.1% hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after timolol 0.1% hydrogel (P
| Original language | English |
|---|---|
| Pages (from-to) | 1552-1557 |
| Number of pages | 6 |
| Journal | Journal of Clinical Pharmacology |
| Volume | 52 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2012 |
Fingerprint
Keywords
- glaucoma
- primary open-angle glaucoma
- Timogel
- Timolol
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. / Quaranta, Luciano; Katsanos, Andreas; Floriani, Irene; Riva, Ivano; Russo, Andrea; Konstas, Anastasios G P.
In: Journal of Clinical Pharmacology, Vol. 52, No. 10, 10.2012, p. 1552-1557.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma
AU - Quaranta, Luciano
AU - Katsanos, Andreas
AU - Floriani, Irene
AU - Riva, Ivano
AU - Russo, Andrea
AU - Konstas, Anastasios G P
PY - 2012/10
Y1 - 2012/10
N2 - Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5% solution administered twice daily versus timolol 0.1% in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5% solution or timolol 0.1% hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after timolol 0.1% hydrogel (P
AB - Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5% solution administered twice daily versus timolol 0.1% in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5% solution or timolol 0.1% hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after timolol 0.1% hydrogel (P
KW - glaucoma
KW - primary open-angle glaucoma
KW - Timogel
KW - Timolol
UR - http://www.scopus.com/inward/record.url?scp=84870462150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870462150&partnerID=8YFLogxK
U2 - 10.1177/0091270011420254
DO - 10.1177/0091270011420254
M3 - Article
C2 - 22110164
AN - SCOPUS:84870462150
VL - 52
SP - 1552
EP - 1557
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
SN - 0091-2700
IS - 10
ER -